Groningen, The Netherlands – 16 September 2025 – InnoCore Pharmaceuticals (“InnoCore”), a leading specialist in long-acting injectable (LAI) drug delivery technologies, today announced a project extension with an existing European biotech partner focused on developing a long-acting injectable protein formulation using its proprietary SynBiosys® technology.
The extended scope of work centers on optimizing formulation performance and release kinetics of a protein-based therapeutic, aiming to further strengthen its market-leading product differentiation. The project is leveraging the versatility of SynBiosys®, InnoCore’s best-in-class biodegradable polymer platform, engineered to stabilize fragile biological molecules and enable controlled, predictable release from injectable depots.
SynBiosys® provides a customizable, scalable, and tunable drug delivery system for proteins, peptides, and complex APIs. Its proprietary polymer matrix protects delicate molecules from aggregation, enzymatic degradation, and acylation, maintaining their structural integrity and therapeutic potency. This allows partners to achieve extended, linear drug release profiles from weeks to months while simplifying formulation scale-up and manufacturing transfer.
Rob Steendam, CTO at InnoCore Pharmaceuticals, said:
“The project expansion builds on an already productive collaboration between our two companies and underscores the strong scientific alignment and mutual commitment to advancing next-generation sustained-release biologic therapies.”
“This new project also represents the 8th new SynBiosys®-based project since the start of 2025, reinforcing our decision to refocus the business on the growing biologics and peptides formulation segment. Our momentum in 2025 continues as we expand our pipeline of SynBiosys® biologics and peptide projects, leveraging our expertise and technology to delivering innovative, science-driven solutions for global pharma and biotech partners that help them achieve their strategic goals.”
With more than 20 years of formulation and polymer development expertise, InnoCore offers a fully integrated approach to LAI drug development, from feasibility and analytical characterization through process optimization, scale-up, and technology transfer. Its state-of-the-art R&D and manufacturing facilities in Groningen, allows a seamless translation of challenging biologics and peptides into stable, scalable, and regulatory-ready sustained-release dosage forms.
-Ends-
For more information, please contact:
Notes to Editors
About InnoCore Pharmaceuticals
InnoCore Pharmaceuticals is a leading drug delivery development provider, formulating peptide and biologic APIs into scalable, biodegradable and tunable Long Acting Injectable (LAI) dosage forms.
The Company’s proprietary polymeric drug delivery platform, SynBiosys®, overcomes the significant technical challenges of translating these complex and fragile molecules into LAI drug products that maintain their essential bioactive characteristics.
Dosage forms can be created for early proof of concept, through to clinical trial usage in an easy-to-scale cGMP form. These formulations can be adapted for use in local or systematic injectable forms for a wide range of therapeutic applications, such as osteoarthritis, rheumatology, oncology, CNS, infectious and cardiometabolic diseases.
InnoCore is a true strategic partner to its biopharma customers working hand-in-hand with them to lay strong foundations for future clinical and commercial success. InnoCore is innovating biologic drug formulation for better treatment outcomes and compliance.
For more information, please see: www.innocorepharma.com.